# Ten63 Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ten63-therapeutics

- Industry: Biotechnology
- Headquarters: Durham, US
- Website: www.ten63tx.com/
- Total disclosed funding: $16M
- Latest round: Series A (May 2, 2023)
- Investors on record: 7

## About

Based in Durham Fwy, North Carolina, US, and founded in 2018, Ten63 Therapeutics provides a platform, Copper, that leverages its proprietary physical models to allow its users to discover new therapeutics to targets previously believed undruggable. In February 2026, Ten63 Therapeutics raised USD 22 million in venture funding from Black Opal Ventures, Cape Fear BioCapital, Chugai Venture Fund, Duke Capital Partners, Gates Foundation Trust, K5 Global, Panorama, RYSE Asset Management, SF Holdings, Alexandria Venture Investments, Draper, Hatteras Venture Partners, Morpheus Ventures, and Yosemite Management.

Ten63 Therapeutics is the developer of a platform that allows anyone to challenge diseases to a chess match, one that is played through evolutionary time. The result is novel therapeutics that are resilient to the emergence of drug resistance and able to modulate previously undruggable targets.  The company plans to utilize the February 2026 funding for development of a computational drug discovery platform and a small-molecule program.

## Funding rounds

- Series A, May 2, 2023, $16M — Alexandria Venture Investments, Hatteras Venture Partners, SOSV, Draper, Sigma Group, Morpheus Ventures
- Seed, Jan 7, 2021 — SOSV, IndieBio
- Seed, Oct 27, 2019 — SOSV, IndieBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed, Series A
- IndieBio (https://capitalatlas.ai/funds/indiebio) — Seed
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series A
- Draper (https://capitalatlas.ai/funds/draper) — Series A
- Sigma Group — Series A
- Morpheus Ventures (https://capitalatlas.ai/funds/morpheus-ventures) — Series A